Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer

Oncology

Volumn 73, Issue 1-2, 2008, Pages 2-8

  Lim, Jae Yun ^a   Cho, Jae Yong ^a,b   Paik, Yong Han ^a   Lee, Dong Ki ^a   Lee, Sang In ^a   Park, Hyo Jin ^a   Lee, Se Joon ^a   Lee, Kwan Sik ^a   Yoon, Dong Sup ^a   Choi, Seung Ho ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Docetaxel chemotherapy; Gastric cancer

Indexed keywords

CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENT CANCER; STOMACH ADENOCARCINOMA; STOMACH SURGERY; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; HEMATOLOGIC DISEASES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; PLATINUM COMPOUNDS; SALVAGE THERAPY; SEVERITY OF ILLNESS INDEX; STOMACH NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 41549147442     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000120027     Document Type: Article

References (26)

1. Jernal A, Thomas A, Murray T, Thun M: Cancer statistics 2002. CA Cancer J Clin 2002;52:23-47.
2. Bae JM, Won YJ, Jung KW, Park JG: Annual report of the Korean central cancer registry program 2000. Cancer Res Treat 2002;34:77-83.
3. Alberts SR, Cervantes A, van de Velde CJH: Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003;14(suppl 2):ii31-ii36.
4. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PD, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-168.
5. Wagner AD, Grothe W, Behl S, Kleber G, Grothey A, Haerting J, Fleig WE: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2005;18:CD004064.
6. Murad AM, Skare NG, Vinholes J, Lago S, Pecego R: Phase II multicenter trial of docetaxel, epirubicin, and 5-fluorouracil (DEF) in the treatment of advanced gastric cancer: a novel, safe, and active regimen. Gastric Cancer 2006;9:99-105.
7. Roth AD, Ajani JA: Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol 2003;14(suppl 2):ii41-ii44.
8. Ajani JA: Evolving chemotherapy for advanced gastric cancer. Oncologist 2005;10(suppl 3):49-58.
9. Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR, Ward C, Iveson T, Nicolson M, Hickish T, Hill M, Oates J: Report of two protocol planned interim analyses in a randomized multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005;92:1976-1983.
10. Budman D, Calabro A, Kreis W: Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Anticancer Drugs 2002;13:1011-1016.
11. Budman D, Calabro A: In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines. Breast Cancer Res Treat 2002;74:41-46.
12. Polyzos A, Tsavaris N, Kosmas C, Gogas H, Vadiaka M, Markopoulos C, Giannopoulos A, Kalahanis N, Stamatiadis D, Kouraklis G, Karatzas G, Liapis C, Syrigos K: Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer. Anticancer Res 2003;23:2917-2923.
13. Pagani O, Sessa C, Martinelli G, Crivellari D, Buonadonna A, Thurlimann B, Hess D, Borner M, Bauer J, Zampino G, Zimatore M, Graffeo R, Riva A, Goldhirsch A: Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Ann Oncol 1999;10:539-545.
14. Kouroussis C, Xydakis E, Potamianou A, Giannakakis T, Kakolyris S, Agelaki S, Sara E, Malamos N, Alexopoulos A, Mavroudis D, Samonis G, Papadouris S, Georgoulias V, Panagos G, for the Greek Breast Cancer Cooperative Group (GBCCG): Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. Ann Oncol 1999;10:547-552.
15. Venturini M, Michelotti A, Papaldo P, Del Mastro L, Bergaglio M, Lionetto R, Lunardi G, Sguotti C, Frevola L, Donati S, Rosso R, Cognetti F: Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients. Ann Oncol 2001;12:1097-1106.
16. National Comprehensive Cancer Network: NCCN practice guidelines for upper gastrointestinal carcinomas. Oncology (Huntingt) 1998;12:179-223.
17. Ajani JA: Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol 2000;18:4001-4002.
18. Wilson D, Hiller L, Geh JI: Review of secondline chemotherapy for advanced gastric adenocarcinoma. Clin Oncol 2005;17:81-90.
19. Vanhoefer U, Wilke H, Harstrick A, Achterrath W, Preusser P, Stahl M, Clemens MR, Thiel E, Flasshove M, Fink U, Trenn G, Seeber S: Phase II study of docetaxel as second-line chemotherapy in metastatic gastric cancer (abstract 1163). Proc Am Soc Clin Oncol 1999;18.
20. Giuliani F, Gebbia V, De Vita F, Maiello E, Di Bisceglie M, Catalano G, Gebbia N, Colucci G: Docetaxel (taxotere) as salvage chemotherapy in patients with advanced gastric cancer. A phase II study of the Southern Italian Oncology Group (GOIM) (abstract 296P). Ann Oncol 2000;11(suppl 4):67.
21. Andre T, Louvet C, Ychou M, Gamelin E, Mousseau M, Carola E, Assadourian S, Gramont AD: Docetaxel-epirubicin as second-line treatment for patients with advanced gastric cancer (abstract 1062). Proc Am Soc Clin Oncol 1999;18.
22. Nguyen S, Rebischung C, Van Ongeval J, Flesch M, Bennamoun M, Andre T, Ychou M, Gamelin E, Carola E, Louvet C: Epirubicin-docetaxel in advanced gastric cancer: two phase II studies as second and first line treatment. Bull Cancer 2006;93:E1-E6.
23. Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y: Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 2006;9:14-18.
24. Baek JH, Kim JG, Sohn SK, Kim DH, Lee KB, Song HS, Kwon KY, Do YR, Ryoo HM, Bae SH, Park KU, Kim MK, Lee KH, Hyun MS, Chung HY, Yu WS: Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study. J Korean Med Sci 2005;20:966-970.
25. Kunisaki C, Imada T, Yamada R, Hatori S, Ono H, Otsuka Y, Matsuda G, Nomura M, Akiyama H, Kubo A, Shimada H: Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma. Anticancer Res 2005;25:2973-2978.
26. Park SH, Choi EY, Bang SM, Cho EK, Lee JH, Shin DB, Lee WK, Chung M: Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes. Anticancer Drugs 2005;16:621-625.